 Heres a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks Biotech Stocks Hitting 52-week Highs May 28 ADC Therapeutics SA NYSE: ADCT IPOed May 15 Aerpio Pharmaceuticals Inc NASDAQ: ARPO announced a collaboration study for razuprotafib in COVID-19 treatment Aileron Therapeutics Inc NASDAQ: ALRN Arca Biopharma Inc NASDAQ: ABIO reacted to its planned foray into COVID-19 treatment argenx SE - ADR NASDAQ: ARGX Bio-Rad Laboratories, Inc. NYSE: BIO BioSpecifics Technologies Corp. NASDAQ: BSTC ChemoCentryx Inc NASDAQ: CCXI GENMAB ASS ADR NASDAQ: GMABannounced positive topline Phase 3 data for daratumumab in light-chain amyloidosis Imara Inc NASDAQ: IMRA Liquidia Technologies Inc NASDAQ: LQDA Mersana Therapeutics Inc NASDAQ: MRSN Protagonist Therapeutics Inc NASDAQ: PTGX Qiagen NV NYSE: QGEN Tenax Therapeutics Inc NASDAQ: TENX Turning Point Therapeutics Inc NASDAQ: TPTX Vermillion, Inc. NASDAQ: VRMLDown In The Dumps Biotech Stocks Hitting 52-week Lows May 28 Zafgen Inc NASDAQ: ZFGNStocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc NASDAQ: KPTI announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients. The data is to be presented at the ASCO 2020 Virtual Scientific Program.The SVd arm, according to the company, showed a statistically significant increase of 47 in median progression-free survival compared to the Vd arm. The overall response rate was 76.4 for the SVd arm compared to 62.3 for the Vd arm.The stock rose 7.71 to 20.25 in after-hours trading.Eisai, Merck Announce ASCO Presentations Eisai Co., Ltd OTC: ESALY and Merck Co., Inc. NYSE: MRK said results from two trials evaluating the formers Lenvima, plus the latters anti-PD-1 therapy Keytruda in patients with unresectable hepatocellular carcinoma, or HCC, with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma, or ccRCC, who progressed following immune checkpoint inhibitor therapy, respectively, showed tumor response.The data is to be presented at the ASCO Virtual Scientific Program.Separately, Merck said a Phase 3 trial, dubbed KEYNOTE-177, evaluating Keytruda for the first-line treatment of patients with microsatellite instability-high, or MSI-H, or mismatch repair deficient, or dMMR, unresectable or metastatic colorectal cancer showed Keytruda significantly reduced the risk of disease progression or death by 40, with a median progression-free survival of 16.5 months compared with 8.2 months for patients treated with chemotherapy, a current standard of care.Merck said the data is scheduled to be presented Sunday in the ASCO meeting.Altimmune Shares Rally On Insider Buying Altimmune Inc NASDAQ: ALT shares were rallying after Venrock Healthcare Capital Partners III filed with the SEC in Form 4 a series of purchases made over this week that has taken its holdings to 3 million shares. A total of 1.304 million shares were accumulated over the week.Immutep Gets 2.41M In RD; Tax Incentive From French Government IMMUTEP LTDS ADR NASDAQ: IMMP said it has received a 2.174-million euro or 2.41 million, RD; tax incentive payment in cash from the French government. The tax credit is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30 of their eligible expenditure.The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761, the company said.In after-hours trading, the stock added 2.40 to 1.28.Roches Cancer Drug Gets Positive European Medicines Agency Committee Recommendation Roche Holdings AG OTC: RHHBY said the European Medicines Agencys Committee for Medicinal Products for Human Use has adopted a positive opinion under conditional marketing authorization for Rozlytrek for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase gene fusion. The CHMP has also recommended Rozlytrek for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer not previously treated with ROS1 inhibitors.Offerings Marinus Pharmaceuticals Inc NASDAQ: MRNS priced its underwritten public offering of 16 million shares at 2.50 per share, for generating gross proceeds of about 40 million. The company expects the offering to close on or about June 2.The stock slid 8.21 to 2.57 in after-hours trading.On The Radar Several companies are scheduled to present data on their pipeline assets in the ASCO 2020 Annual Meeting Virtual Scientific Program. Some of the companies presenting Friday include: Arvinas Inc NASDAQ: ARVN Trillium Therapeutics Inc NASDAQ: TRIL Cardiff Oncology Inc NASDAQ: CRDF Iovance Biotherapeutics Inc NASDAQ: IOVA Blueprint Medicines Corp NASDAQ: BPMC Allogene Therapeutics Inc NASDAQ: ALLO Deciphera Pharmaceuticals Inc NASDAQ: DCPH GENMAB ASS ADR NASDAQ: GMAB AVEO Pharmaceuticals, Inc. NASDAQ: AVEO Amgen, Inc. NASDAQ: AMGN Clovis Oncology Inc NASDAQ: CLVS IMMUTEP LTDS ADR NASDAQ: IMMP Heat Biologics Inc NASDAQ: HTBX Autolus Therapeutics Ltd - ADR NASDAQ: AUTL Oncolytics Biotech, Inc. NASDAQ: ONCY Athenex Inc NASDAQ: ATNX Harpoon Therapeutics Inc NASDAQ: HARP Gossamer Bio Inc NASDAQ: GOSS ImmunoGen, Inc NASDAQ: IMGN Merus NV NASDAQ: MRUS CytomX Therapeutics Inc NASDAQ: CTMX Corvus Pharmaceuticals Inc NASDAQ: CRVS Pfizer Inc. NYSE: PFE CELYAD SAADR NASDAQ: CYAD Immunomedics, Inc. NASDAQ: IMMU Xencor Inc NASDAQ: XNCR MacroGenics Inc NASDAQ: MGNX DelMar Pharmaceuticals Inc NASDAQ: DMPI Salarius Pharmaceuticals Inc NASDAQ: SLRX AstraZeneca plc NYSE: AZN Genocea Biosciences Inc NASDAQ: GNCA NextCure Inc NASDAQ: NXTC Spring Bank Pharmaceuticals Inc NASDAQ: SBPH Adaptimmune Therapeutics PLC NASDAQ: ADAP ZIOPHARM Oncology Inc. NASDAQ: ZIOP Agios Pharmaceuticals Inc NASDAQ: AGIO Oncternal Therapeutics Inc NASDAQ: ONCT Roche Aptose Biosciences Inc NASDAQ: APTO Kura Oncology Inc NASDAQ: KURA Innate Pharma SA NASDAQ: IPHA Imv Inc NASDAQ: IMV: MEI Pharma Inc NASDAQ: MEIP TapImmune Inc. common stock NASDAQ: MRKR Inovio Pharmaceuticals Inc NASDAQ: INOSee more from Benzinga The Daily Biotech Pulse: Cumberlands Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas Mercks Coronavirus Plan Of Attack: 2 Partnerships, MA; Deal Aimed At Treatment, Vaccine DevelopmentC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 